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Abstract 
 
Excessive reactive oxygen species (ROS) can damage proteins, lipids, and DNA, which result in 
cell damage and death. The outcomes can be acute, as seen in stroke, or more chronic as 
observed in age-related diseases such as Parkinson’s disease. Here we investigate the antioxidant 
ability of a novel synthetic flavonoid, Proxison (7-decyl-3-hydroxy-2-(3,4,5-trihydroxyphenyl)-4-
chromenone), using a range of in vitro and in vivo approaches. We show that, while it has radical 
scavenging ability on par with other flavonoids in a cell-free system, Proxison is orders of 
magnitude more potent than natural flavonoids at protecting neural cells against oxidative stress 
and is capable of rescuing damaged cells. The unique combination of a lipophilic hydrocarbon tail 
with a modified polyphenolic head group promotes efficient cellular uptake and moderate 
mitochondrial enrichment of Proxison. Importantly, in vivo administration of Proxison demonstrated 
effective and well tolerated neuroprotection against cell loss in a zebrafish model of dopaminergic 
neurodegeneration.  
 
Introduction 
 
Oxidative stress has been implicated in a wide range of age-related conditions, including heart 
disease, cancer, diabetes and neurodegenerative diseases1-4. In healthy cells there is a balance 
between the production of reactive oxygen species (ROS) and their removal by antioxidants, with 
discrete generation of ROS playing an essential role regulating cell signaling and function5,6. 
Excessive production of ROS results in oxidative stress causing aberrant cell signaling, damage to 
cellular components, and subsequent disease. A number of ROS are involved in cellular oxidative 
stress, including superoxide radicals, hydrogen peroxide and hydroxyl radicals. The chemical 
reactivity of each of these and their site of production within the cell determines their ability to 
damage cellular components7,8. Mitochondria produce superoxide radicals and hydrogen peroxide 
as by-products of oxygen consumption. There are multiple sites of superoxide production in the 
mitochondrial electron transport chain including NADH-ubiquinone oxidoreductase of complex I, 
the coenzyme Q pool as well as complexes II and III 9-13. Acute increased superoxide production at 
complex I occurs in stroke through a conserved mechanism14,15. This results in oxidative damage 
and neuronal cell death by mechanisms that include increased H2O2 release16,17. 
 Chronic exposure to oxidative stress has been implicated in numerous age-related 
degenerative conditions, including Parkinson’s disease where age is the most significant risk 
factor. Post-mortem analysis of Parkinson’s patients brains showed evidence of oxidative damage 
and mitochondrial complex I dysfunction in the substantia nigra3,18-21. During earlier stages of 
Parkinson’s disease, patients also show evidence of mitochondrial dysfunction and oxidative 
damage in their platelets and plasma22,23. However, it is difficult to determine when in the disease 
process this damage occurs and how influential it is in disease progression. The use of novel 
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potent antioxidants in combination with refined disease models will be key to definng the role for 
oxidative stress in disease pathogenesis, and to pinpoint when and where this occurs. If it proves 
to be an early and pivotal defect, it opens up an exciting new field of potential therapeutic targets 
for intervention of age-related diseases. 
 Flavonoids are a large group of polyphenolic antioxidant compounds found in plants that 
can directly scavenge ROS. Their antioxidant activity is a result of the efficiency by which they can 
donate hydrogen atoms from their multiple hydroxyl groups to free radicals, a mechanism that is 
facilitated by the extended conjugation afforded through the π-electron system of the core 
flavonoid molecular scaffold24,25. The dietary flavonoids, quercetin and myricetin are amongst the 
most potent24-26, although they are poorly absorbed from the diet27-29. Furthermore, their 
physicochemical attributes mitigate against effective uptake and distribution in the cell25. However, 
cell absorption characteristics and bioactivity can be improved significantly by chemical 
modification of the parent myricetin compound through attachment of lipophilic alkyl chains of 
different lengths and by removal of hydroxyl groups that do not contribute to the antioxidant 
potential. A rational drug design approach, based on structure-activity relationships of natural and 
modified flavonoid antioxidants led to Proxison (7-decyl-3-hydroxy-2-(3,4,5-trihydroxyphenyl)-4-
chromenone) as one of the most promising of these synthetic compounds29. This compound 
comprises of a straight chain C10 hydrocarbon tail covalently linked to a flavonoid head group 
similar to myricetin (Figure 1a). In terms of prevention of lipid peroxidation, Proxison exhibited 
superior protection when compared to structurally similar compounds30. Recently, Proxison was 
shown to reduce proliferation of a breast cancer cell line at high concentrations, but its antioxidant 
functions at physiological concentrations have not been investigated31. 
 The aim of this study was to examine the antioxidant and cell protective activity of Proxison 
using in vitro and in vivo model systems. This compound had potent radical scavenging 
capabilities in a cell-free radical scavenging model and was highly protective in a neuronal cell 
model of acute oxidative stress. In vivo, Proxison efficiently protected against 6-hydroxydopamine 
(6-OHDA) induced death of dopaminergic neurons in a zebrafish model. We demonstrate that 
Proxison is highly cell permeable and shows enrichment in the cytosol, especially to mitochondria, 
a key characteristic that may be critical for its protective function in neurons. Therefore, Proxison 
represents a novel class of synthetic antioxidant, which is well tolerated and effective in promoting 
cell survival in conditions where oxidative stress is the major cause of cell death. 
 
Results 
 
Radical scavenging capabilities of flavonoid antioxidants 
To directly compare the scavenging ability of Proxison to the structurally related natural flavonoids, 
myricetin and quercetin (Figure 1a), we used the stable free radical galvinoxyl in a cell-free assay. 
Galvinoxyl has one unpaired electron, which is extensively delocalised throughout the molecule 
and gives rise to a characteristic electron paramagnetic resonance (EPR) spectrum as a result of 
the interaction of the electron spin with the nuclear spins of protons in the molecule. All three 
flavonoids efficiently scavenged galvinoxyl radicals in this chemical model system and mediated a 
concentration-dependent reduction in EPR signal intensity (Figure 1b,c). The radical scavenging 
ability of Proxison was equal to that of myricetin despite having two less hydroxyl groups and 
increased hydrophobicity, and both compounds were more than twice as potent as quercetin, 
which has one less hydroxyl group on the B-ring (Figure 1d). 
 
Protection against acute oxidative stress in cells 
Next, we compared Proxison to myricetin, quercetin, and other antioxidants for their ability to 
protect against oxidative stress in a neural cell culture model, SH-SY5Y neuroblastoma cells. 
These cells were treated with the organic peroxide tert-butyl hydroperoxide (tBHP) to generate 
peroxyl radicals and cause acute oxidative stress32. Cells exhibited a significant reduction in cell 
metabolic activity (MTS tetrazolium reduction assay) after 5 h treatment with 200-800 µM tBHP 
(Supplementary Figure 1). 400 µM tBHP was found to be optimal as it elicited a robust and 
reproducible stressor effect in this cell-based assay. 
 Proxison used at 5 and 10 µM significantly prevented the reduction in cell metabolic activity 
caused by 400 µM tBHP treatment (Figure 2a). Due to its strong reducing capabilities, 
concentrations above 50 µM Proxison caused signs of cytotoxicity. Quercetin showed significant 
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protection between 25-100 µM, however, a 10-fold higher concentration was required to exert a 
level of protection similar to Proxison. In contrast, myricetin showed no appreciable protection 
against tBHP even at 100 µM. Other antioxidants, including vitamin E, Idebenone (a synthetic 
derivative of coenzyme Q10) and coenzyme Q10 showed no protection in this assay (Figure 2a). 
Furthermore, morphological signs consistent with lipid peroxidation, including membrane blebbing, 
which were observed by 5 h of tBHP treatment, were rescued by Proxison and high-dose 
quercetin, but not myricetin (Figure 2b). 
 Oxidative stress can also result in cytotoxicity, so we next assessed cell death by the 
lactate dehydrogenase (LDH) assay. tBHP treatment of SH-SY5Y cells for 16 h caused a 
significant deterioration of cell membrane integrity resulting in leakage of cytoplasmic LDH into the 
media. Proxison (5-10 µM) and a high concentration of quercetin (100 µM, but not 25 µM) 
significantly prevented the cytotoxic effects of tBHP, while myricetin and vitamin E offered no 
protection (Figure 2c). Similarly, we further confirmed the cytoprotective capabilities of Proxison 
with a propidium iodide (PI) exclusion assay (Figure 2d). Less than 30% of tBHP-treated cells were 
viable after 16 hours as determined by this assay. However, pre-incubation with Proxison at 10 
µM, but not 1 µM, protected against cell death to levels that were not significantly different from 
non-treated control cells (Figure 2d). 
We further confirmed the protective capabilites of Proxison with an independent clone of 
SH-SY5Y cells (Supplementary Movies 1 and 2), and demonstrated that 1 µM Proxison was 
sufficient to protect these cells from tBHP induced cell death (Supplementary Figure 2). We also 
compared Proxison, myricetin, and quercetin for their ability to protect a completely different neural 
cell line, Neuroscreen-1™ (NS-1), from peroxide induced toxicity. Similar to the SH-SY5Y results a 
low dose of Proxison (0.5 - 5 µM) or a high dose of quercetin (25 - 50 µM) could protect NS-1 cells 
from tBHP-induced cytotoxicity, while myricetin did not exhibit any protective properties in this cell 
culture model (Supplementary Figure 3). 
 
Flavonoid antioxidant cellular uptake and intracellular localisation 
Given that the antioxidants were similarly potent in the cell-free galvinoxyl assay, the differential 
protective properties of Proxison, quercetin and myricetin in cells could be due to differences in 
cellular uptake or subcellular localisation. To investigate the intracellular uptake and localisation of 
the different flavonoids we took advantage of the endogenous fluorescence characteristics of these 
molecules33,34. Intrinsic green fluorescence of Proxison, myricetin and quercetin was confirmed 
using a plate reader with excitation 485 nm and emission 520 nm (Supplementary Figure 4).   
 Cells were incubated with Proxison (10 µM), quercetin (100 µM), or myricetin (100 µM) for 
2 h and washed out before processing for confocal imaging. Whereas quercetin accumulated in 
nuclei, Proxison was localised to the cytoplasm with some enrichment in filamentous perinuclear 
structures (Figure 3a). The subcellular localisation of Proxison was investigated further by staining 
with the mitochondrial marker, Mitotracker Deep Red. Although Proxison was observed throughout 
the cytoplasm, the stronger filamentous staining co-localized with Mitotracker Deep Red 
suggesting some form of enrichment at mitochondria (Figure 3b). Despite an emission profile 
similar to quercetin (Supplementary Figure 4), myricetin did not appear to be taken up into cells, as 
the fluorescence observed in treated cells was similar to the background in control cells (Figure 
3a). Cellular uptake was further investigated by FACS analysis showing significant intracellular 
levels of Proxison and quercetin, whereas myricetin was undetectable (Figure 3c). This suggests 
the lack of protective activity of myricetin compared to Proxison and quercetin reflects its inability to 
enter cells. In summary, Proxison was efficiently taken up by cells and was localised to the 
cytoplasm with moderate enrichment to mitochondria. 
 Given that Proxison exhibited some co-localization with a mitochondrial marker, we decided 
to test its protective capabilities directly against a known mitochondrial antioxidant, MitoQ35. As 
determined by the LDH release assay, both Proxison and MitoQ at 10 µM significantly protected 
cells against a high-dose of tBHP (400 µM), and Proxison was at least twice as potent as MitoQ in 
this acute cytotoxicity assay (Figure 3d).  
   
Proxison prevents intracellular radical production and downstream effects of oxidative 
stress 
To assess intracellular scavenging potency of Proxison, the ROS biosensor CellROX® Deep Red 
was used36. Using far-red fluorescence intensity as a read-out of radical production, tBHP was 
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found to significantly increase intracellular ROS in SH-SY5Y cells, and Proxison and quercetin, but 
not myricetin, were capable of preventing this ROS production (Figure 4a). Quantification of far-red 
signals confirmed Proxison and high-dose quercetin effectively blocked the accumulation of tBHP-
generated radicals to the level of untreated cells (Figure 4b). 
 A major mechanism in the cellular defense against oxidative stress involves activation of 
the Nrf2-Keap1 antioxidant response signaling pathway35. This requires nuclear localization of a 
key transcription factor NRF2 to activate a number of antioxidant genes37-39. To determine whether 
Proxison is capable of preventing downstream consequences of tBHP induced oxidative stress we 
analysed subcellular localisation and action of NRF2. Nuclear NRF2 increased upon tBHP 
treatment, an effect that was significantly prevented in the presence of Proxison (Figure 5a,b). To 
confirm NRF2 was active in the nucleus, we quantified expression of two NRF2-regulated 
antioxidant response element (ARE) genes, NQO1 and HMOX1. The increased transcription of 
both ARE genes caused by tBHP treatment was significantly attenuated by Proxison (Figure 5d). 
The transcript levels of NRF2 itself were unaffected agreeing with the known post-translational 
mechanism of action for this transcription factor39. 
 To determine whether Proxison protects against ROS-induced oxidative damage of nucleic 
acids, we looked for the presence of 8-hydroxy-2'-deoxyguanosine (8-OHdG) in the cell, a marker 
of oxidative damage to DNA and RNA. 8-OHdG is a major product of nucleic acid oxidation and its 
concentrations within a cell act as a read-out of oxidative stress induced damage40. Proxison was 
able to completely inhibit the accumulation of 8-OHdG marks in cells caused by tBHP treatment 
(Figure 5a, c). 
 
Proxison protects dopaminergic neurons in a zebrafish model 
To determine the ability of Proxison to protect neurons in an intact animal and to detect potential 
toxic side-effects, we assessed its ability to protect dopaminergic neurons in the brain of zebrafish 
embryos. The neurotoxic compound 6-hydroxydopamine (6-OHDA) was used to selectively induce 
death of dopaminergic and noradrenergic neurons in this model, as measured by counts of 
tyrosine hydroxylase (TH) positive neurons41,42. At 24 hours post fertilisation (hpf), zebrafish 
embryos were treated with 6-OHDA (250 µM for 24 h) in the absence or presence of the 
antioxidants Proxison or quercetin. At 48 hpf embryos were fixed and immunostained for TH prior 
to collection of z-stack images of each embryo head by confocal microscopy (Figure 6a), and the 
number of TH positive cells were quantified (Figure 6b). Embryos treated with 6-OHDA 
consistently had 30% less TH positive cells than control embryos, while co-incubation with 
Proxison showed significant protection against 6-OHDA-induced neuronal cell loss (Figure 6a,b). 
Quercetin also afforded protection against 6-OHDA induced toxicity, but was less robust than 
Proxison. None of the treatments reduced survival or perturbed normal development of the 
embryos, showing that Proxison was not toxic and was well tolerated at the concentrations used 
that elicited neuroprotective effects in vivo. 
 
Discussion 
 
Here we characterise the antioxidant profile of a novel synthetic flavonoid, Proxison. Although the 
intrinsic radical scavenging activity of Proxison is similar to its natural counterparts, it possesses a 
superior ability to protect against acute oxidative stress in cellular contexts. The lipophilic tail of 
Proxison enhances its cellular uptake and may improve its stability30. The subcellular localization of 
Proxison is mostly cytoplasmic with some enrichment at mitochondria, while quercetin localizes to 
the nucleus. Although myricetin was as potent as Proxison in a cell-free radical scavenging assay, 
it was poorly taken up by cells, possibly due to its instability at neutral pH or its low lipophilicity43,44. 
Quercetin was a less potent antioxidant scavenger in the cell-free assay, but it was readily taken 
up by cells, and it accumulates in the nucleus for, as yet, unknown reasons33. This localization 
could explain why a 10-fold higher concentration of quercetin is needed to provide a similar level of 
protection as Proxison, which is cytoplasmic, against tBHP-induced toxicity. The superior potency 
of Proxison may also be due to the phenoxyl radical (the oxidized form of Proxison) being recycled 
by intracellular antioxidants, or other reductive pathways, back to Proxison, as occurs for vitamin 
E45. Flavonoid antioxidants are also capable of chelating transition metal ions such as iron or 
copper thereby limiting the breakdown of tBHP to its initiating free radical products or inhibiting lipid 
peroxidation through the Fenton reaction25. Proxison may therefore be able to exert a protective 
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effect by a mechanism other than direct scavenging of free radicals by hydrogen atom electron 
transfer reactions, a mechanism supported by structure-activity studies on a wide range of 
flavonoids, including myricetin46. 
 We demonstrated that Proxison scavenges intracellular ROS and prevents downstream 
oxidative damage to both membranes and nucleic acids resulting from tBHP treatment. Induction 
of the NRF2 antioxidant response pathway was significantly dampened by Proxison, but not 
eliminated. Therefore, Proxison can act in conjunction with other cellular antioxidant responses to 
acute oxidative stress to promote cell survival. Importantly, the studies in zebrafish embryos 
showed that Proxison, and to a lesser extent quercetin, is capable of protecting dopaminergic 
neurons against acute neuronal loss in an intact animal. It is important to demonstrate that this 
neuronal loss is due to oxidative stress induced by 6-OHDA, and zebrafish models that directly 
measure oxidative stress in embryos have recently been established47. 
 There are currently several published classes of synthetic mitochondrial-targeted 
antioxidants. The Mito compounds contain a triphenylphosphonium ion (TPP), which has a positive 
charge, which attracts it to the mitochondrial matrix. The TPP ion has been attached to a number 
of known antioxidants, including vitamin E and coenzyme Q1035,48. MitoQ compounds are taken up 
into cells and accumulate in mitochondria only when the membrane potential is intact, which may 
not always be the case in damaged cells35,48,49. MitoQ was tested in a phase II clinical trial for 
symptomatic Parkinson’s disease patients. However, there was no change in the rate of disease 
progression50. Currently MitoQ is due to undergo a phase II clinical trial for chronic kidney disease 
(ClinicalTrials.gov Identifier: NCT02364648). SS peptides are short positively charged peptides 
that are cell permeable and localise to mitochondria51,52. SS peptide localization is due to their 
lipophilicity and positive charge and is partially reliant on an intact mitochondrial membrane 
potential52,53. The lead SS peptide, SS-31 (Bendavia; MTP-131), is protective in rodent models of 
amyotrophic lateral sclerosis and myocardial infarction54,55. Bendavia is currently in clinical trials for 
heart failure (ClinicalTrials.gov Identifier: NCT02388464) and genetically confirmed mitochondrial 
disease (ClinicalTrials.gov Identifier: NCT02805790). The plant-derived antioxidants, 
plastoquinone and thymoquinone, have also been modified to accumulate in mitochondria56. These 
mitochondrially-targetted antioxidants show protection in a rat stroke model57. Proxison exhibits 
some mitochondrial enrichment as a likely consequence of the lipophilicity of a long hydrocarbon 
tail combined with the unique redox properties of the polyphenolic head group58. However, it is not 
yet known whether this enrichment is due to the unique properties of mitochondrial lipids or 
proteins that may have affinity for Proxison, or if the enrichment requires an intact mitochondrial 
membrane potential. 
This novel antioxidant can be applied to investigate oxidative stress in disease models, like 
α-synucleinopathies and other neurodegeneration models. This would provide insight into disease 
processes and aid in development of novel treatments. In addition, Proxison could have 
applications for regenerative medicine where oxidative stress has been implicated in poor cell 
survival of transplanted cells, with the advantage that the molecule can be pre-loaded into cells 
prior to transplantation. Proxison could also have applications for conditions, such as stroke or 
cardiac infarction, in which a temporary, but acute, exposure to oxidative stress is experienced, as 
well as diseases in which oxidative stress and mitochondrial dysfunction are core features.  
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Methods 
 
Galvinoxyl Electron Paramagnetic Resonance Spectroscopy 
Galvinoxyl (182 µM, Sigma) was mixed with 2.5 µM or 5 µM Proxison (7-decyl-3-hydroxy-2-(3,4,5-
trihydroxyphenyl)-4-chromenone, Antoxis), myricetin (Sigma) or quercetin (Sigma) in DMSO. Five 
minutes after addition measurements were taken using the Magnettech Miniscope MS200 EPR 
machine. Settings: centre field= 3364.05 G; Sweep= 69.59 G; Sweep Time= 20 s; Smooth= 0 s; 
Steps= 4096; Number of passes= 1 pass; Modulation= 1.5 G; Power= 7dB; Gain= 1E2. The 
percentage radical scavenging ability was calculated from the EPR signal intensity with antioxidant 
relative to the signal intensity of galvinoxyl alone. 
 
Cell Culture 
The SH-SY5Y cell line was a kind gift from Professor David Porteous (Centre for Genomic and 
Experimental Medicine, University of Edinburgh). They were cultured at 37°C in a humidified 
atmosphere of 5% CO2 in DMEM supplemented with 10% FBS, 2 mM L-glutamine and 1 mM 
sodium pyruvate (all from Life Technologies). When cells were 70-80% confluent they were 
passaged using trypsin (Life Technologies). An independent clone of SH-SY5Y cells was kindly 
provided by Dr Michael J Devine (Institute of Neurology, UCL). The rat Neuroscreen™-1 (NS-1) 
cells (Thermo Scientific, R04-0001-AP) were cultured in NS-1 medium consisting of RPMI 1640 
basal medium (Hyclone, SH30027) supplemented with 10% horse serum (Life Technologies, 
26050-088), 5% FBS and 2 mM L-glutamine. 
 
MTS Assay 
The MTS assay was performed using the Promega CellTiter 96® Aqueous MTS Reagent Powder 
(Promega) with phenazine methosulphate (PMS; Sigma) as the electron coupler. SH-SY5Y cells 
were seeded at 1.25x105 cells/cm2 in 96-well plates and incubated for 24 hours when either tBHP 
(Sigma) was added or cells were pre-incubated with antioxidants Proxison, myricetin, quercetin, 
vitamin E (Sigma), Idebenone (Antoxis) or coenzyme Q10 (Sigma) for 30 minutes before tBHP 
(400 µM) addition. Five hours later phase-contrast images were collected with an Olympus IX51 
inverted microscope and the MTS assay was performed, according to manufacturer’s instructions. 
Briefly, 100 µl of PMS (0.92 mg/ml) was added to 2 ml of MTS (2 mg/ml), and then 20 µl of the 
MTS/PMS mixture was added to each well of a 96-well plate containing 100 µl of conditioned 
media. The plate was incubated at 37°C/5% CO2 for 1 hour when the absorbance at 490 nm was 
measured using the FLUOstar OMEGA microplate reader (BMG LabTech). The background 
absorbance from the media incubated with MTS/PMS was subtracted from the well absorbance to 
give the sample absorbance. The percentage of the sample absorbance relative to control treated 
cells absorbance gave the % metabolic activity. NS-1 cells were seeded at 3.125x104 cells/cm2 on 
6 µg/cm2 collagen I coated 96-well plates, and differentiation was initiated the following day 
medium by replacing medium with a 1 in 10 dilution of NS-1 medium supplemented with 50 ng/ml 
nerve growth factor β (NGFβ) (Sigma, N2513). On day 3 of differentiation cells were treated with 
tBHP (200 µM) for 16 hours before an MTS assay was performed as described above. 
 
LDH Assay 
The LDH-Cytotoxicity Assay Kit II (Source Bioscience) was used to quantify cell death due to tBHP 
treatment. SH-SY5Y cells were pre-incubated with antioxidants for 30 minutes when 400 µM tBHP 
was added to the antioxidants for 16 hours. Thirty minutes before the end of tBHP treatment cell 
lysis buffer was added to the high control wells. At the end of tBHP treatment the 96-well plate was 
gently mixed to distribute the LDH in the media. The plate was then centrifuged at 600g for 10 
minutes to precipitate cells and debris. 10 µl of media from each well was moved to a new 96-well 
plate and 100 µl of LDH reaction mix was added to each well. The plate was then incubated at 
room temperature for 30-60 minutes when absorbance was read using the FLUOstar OMEGA 
microplate reader. The 650 nm reference absorbance was subtracted from the 450 nm absorbance 
reading to give the well absorbance. The background absorbance was subtracted from the well 
absorbance to give the sample absorbance. The sample absorbance was subtracted from control-
cultured cells (low control) and divided by the cells that had been lysed (high control) minus the 
control cells (low control) to give the % cytotoxicity. 
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PI FACS 
The propidium iodide (PI) assay was performed to assess Proxison protection against tBHP-
induced toxicity. SH-SY5Y cells were pre-incubated with Proxison (1 or 10 µM) for 30 minutes 
when 400 µM tBHP was added for 16 hours. Then the media was collected and cells were lifted 
using trypsin, washed in PBS with 2% FBS and resuspended in 100 µl PBS with 2% FBS. This cell 
solution was filtered and incubated with PI (1 µg/ml) at room temperature for 10 minutes. Then 300 
µl PBS with 2% FBS was added to dilute the cells. Cells were kept on ice until FACS analysis data 
was collected using the FACS Calibur and post-acquisition analysis was performed using FlowJo 
X. The unstained sample was used to create gates to determine PI positive cells and the 
percentage of PI positive and negative cells was calculated. 
 
Videomicroscopy 
Live cell imaging of SH-SY5Y cells treated with tBHP (400 µM) in the absence or presence of 
Proxison (1 µM) was obtained with the Cell-IQ system (CM Technologies) for 5 hours 
(Supplementary Movies 1 and 2). 
 
Antioxidant Fluorescence 
Proxison, myricetin and quercetin (1 mM) in DMSO were added to a 96-well plate in triplicate. The 
intrinsic fluorescence of each compound was measured using a FLUOstar OMEGA microplate 
reader (BMG LabTech) with excitation 485 nm and emission 520 nm. DMSO background 
fluorescence was subtracted. 
 
Antioxidant Subcellular Localisation 
SH-SY5Y cells were seeded on coverslips and loaded with the following antioxidants for 2 hours; 
10 µM Proxison, 100 µM quercetin, 100 µM myricetin or DMSO as a vehicle control. Then cells 
were fixed in 4% PFA (Sigma) and counterstained with 4',6-diamidino-2-phenylindole (DAPI; Life 
Technologies) for 10 minutes. Coverslips were washed in MilliQ water and mounted onto slides 
using Vectashield (Vector Laboratories, H1000). Images were taken using the 63x objective of the 
Leica TCS SPE confocal microscope. The 488 nm laser was used to excite the antioxidants and 
emission was measured between 496-595 nm. To observe Proxison subcellular localization, SH-
SY5Y cells on coverslips (as above) were loaded with 100 nM Mitotracker Deep Red (Life 
Technologies) for 20 minutes before the addition of 10 µM Proxison for 2 hours. The cells were 
then fixed in 4% PFA and processed as described above. The 635 nm laser was used to excite 
Mitotracker Deep Red. 
 
Intracellular Antioxidant Fluorescence (FACS) 
SH-SY5Y cells were treated as above for antioxidant localisation but 2 hours after antioxidant 
addition cells were lifted using trypsin, washed in PBS with 2% FBS and resuspended in 100 µl 
PBS with 2% FBS. The cell solution was then filtered and cells were incubated with PI (1 µg/ml) on 
ice. 300 µl PBS with 2% FBS was added. Cells were kept on ice until fluorescence was analysed 
using the FACS Calibur. Post-acquisition analysis using FlowJo X was used to exclude PI positive 
cells and to graph the cells positive for green (FL-1) fluorescence. Mean green fluorescence was 
calculated with FlowJo X. 
 
CellROX® Deep Red Assay 
SH-SY5Y cells were seeded at 6.25x104 cells/cm2 on 13 mm coverslips. 24 hours later cells were 
incubated with 10 µM CellROX® Deep Red (Life Technologies) and 2.8 µg/ml Hoechst 33342 
(Fluka) for 30 minutes. CellROX® and Hoechst 33342 were removed and cells were washed three 
times with complete medium. Proxison (10 µM) or DMSO vehicle was added for 30 minutes, and 
then 400 µM tBHP was added. One hour after tBHP addition, the coverslips were placed into an 
Attofluor® Cell Chamber (Life Technologies) holder and washed with Hank’s balanced salt solution 
(HBSS) with calcium and magnesium. Images were taken on the Zeiss Observer of phase 
contrast, CellROX® Deep Red and Hoechst 33342 fluorescence. Random areas (n=5-6) of each 
coverslip were imaged. Post-acquisition analysis was performed using Volocity. A small area 
around each apparent cell nuclei was selected in all images and the mean fluorescence in arbitrary 
units (au) in these areas was calculated. The mean and standard error of mean (SEM) was 
calculated (n=4). 
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Immunocytochemistry and quantification 
SH-SY5Y cells were seeded at 1.25x105 cells/cm2 on coverslips and incubated for 24 hours prior 
to addition of Proxison or vehicle (DMSO) for 30 minutes. Then 400 µM tBHP was added for 4.5 
hours when cells were fixed with 4% PFA for 20 minutes and washed three times with PBS. 
Immunocytochemistry was performed by the addition of blocking buffer (0.1% Triton X-100 or 0.3% 
Triton-X100 for nuclear staining, 2% goat serum, PBS) for 30 minutes. Primary antibodies rabbit 
IgG NRF2 (1:800, C-20, Santa Cruz), mouse IgG2b 8-OHdG (1:1000, 15A3, abcam) in blocking 
buffer were added to cells for 16 hours at 4°C, when they were washed 3 times in PBS with 0.1% 
Triton X-100. Secondary antibodies (Life Technologies) in blocking buffer were incubated with cells 
for 2 hours at room temperature in foil, when they were washed 3 times in PBS with 0.1% Triton X-
100. DAPI (10-50 µg/ml, Life Technologies) in PBS was added for 10 minutes. Cells were imaged 
using Leica TCS SPE confocal microscope. NRF2 images were quantified using ImageJ. The z-
stack images were flattened and a mask was created using the DAPI channel. This mask was then 
used to calculate the nuclear red fluorescence intensity. The mean fluorescence from each image 
(2-4 images) and from each coverslip was calculated. The 8-OHdG images were quantified using 
ImageJ. The z-stack images were flattened and a mask was created using the DAPI channel, this 
mask included the nuclei and the area surrounding the nuclei by reducing the threshold. This mask 
was then used to calculate the nuclear green fluorescence intensity. The mean fluorescence from 
each image was calculated with ImageJ. 
 
RT-qPCR 
SH-SY5Y cells were loaded with Proxison or DMSO as a control for 30 minutes before 400 µM 
tBHP was added for 4.5 hours when cells were lifted with trypsin and pelleted. RNA extraction was 
performed using the Epicentre MasterPure™ Complete DNA and RNA Purification Kit (Epicentre, 
MC85200), according to manufacturer’s instructions. RNA concentration was quantified using a 
Nanodrop spectrophotometer. Total RNA (1 µg) was used for cDNA synthesis. RNase-free water 
was added to the RNA to give a 10 µl sample. The samples were incubated with 1 µl dNTP mix (10 
mM Life Technologies) and 1 µl random primers (50 ng/µl, Thermo Fisher) at 65°C for 5 minutes 
and then chilled on ice. After brief centrifugation, 4 µl 5x First strand buffer (Life Technologies), 2 µl 
0.1M DTT (Life Technologies) and 1µl RNAse OUT (40 units/µl, Life Technologies) were added. 
The contents was incubated at 37°C for 2 minutes. Then 1 µl M-MLV reverse transcriptase (200 
units/µl, Life Technologies) or 1 µl RNase-free water for the negative reverse transcriptase sample 
was added. This was mixed and incubated at room temperature for 10 minutes when it was moved 
to 37°C for 60 minutes. The reaction was inactivated by incubation at 90°C for 10 minutes. The 
cDNA mix was placed on ice and 80 µl RNase-free water was added. The cDNA samples were 
then ready for RT-qPCR. qPCR was performed using the Roche LightCycler® 480 System with the 
Universal Probe Library (UPL) (Roche). The Roche UPL Assay design centre was used to design 
intron-spanning primers with a specific UPL probe for each gene (TBP F-
gaacatcatggatcagaacaaca R-atagggattccgggagtcat Probe 87; NRF2 F-acacggtccacagctcatc R-
tgcctccaaagtatgtcaatca Probe 18; HMOX1 F-cagtcaggcagagggtgatag R-agctcctgcaactcctcaaa 
Probe 42; NQO1 F-acgctgccatgtatgacaaa R-ggatcccttgcagagagtaca Probe 9). Reactions (10 µl) 
containing primers, UPL Probe, LightCycle® 480 Probes Master mix (Roche) and PCR water were 
performed in 386-well plates as described in the manufacturer’s instructions. The results were 
normalized to RNA levels of TATA-binding protein (TBP). 
 
Treatment of zebrafish embryos with 6-hydroxydopamine (6-OHDA) and neuroprotective 
compounds 
All zebrafish were maintained under Home Office Project Licence No.: 60/4196 and all 
experiments were performed in accordance with the relevant guidelines and regulations, and 
approved by the Animal Welfare and Ethical Review Body of the University of Edinburgh. The Wik 
wild-type strain of zebrafish was used for this study, and they were maintained in standard 
conditions59. Clutches of embryos were obtained from single pair matings to ensure all embryos 
were at the same developmental stage across treatments.  At 24 hours post fertilisation (hpf) 
embryos were split into groups of 24-30 embryos and treated with 250 µM 6-OHDA (162957, 
Sigma) or 250 µM 6-OHDA + 10 µM Proxison or quercetin in 3 ml embryo medium for 24 hours 
(water for control). At 48 hpf embryos were fixed in 4% paraformaldehyde in PBS for 45min. 
	 9 
Samples were then blocked (2% bovine serum in 0.1% PBS-triton) for 1h at room temperature. A 
mouse monoclonal anti-TH antibody (1:1000 diluted in blocking buffer, MAB318, Millipore) was 
used as the primary antibody and incubated with the samples overnight at 4°C. The next day 
samples were washed in 0.1% PBS-T, followed by incubation with a secondary antibody Cy3 
donkey α-mouse (1:200 diluted in blocking buffer, 715165150, Jackson Immuno) overnight at 4°C. 
Samples were then washed and mounted in 70% glycerol in PBS. Embryos were imaged by 
confocal microscopy (LSM710, Zeiss, Oberkochen, Germany), and Z-stacks were taken through 
the head ensuring all cells could be quantified. Cell counts were performed using ImageJ. The 
observer was blinded for all quantifications of confocal images. 
 
Statistical Analysis 
Statistical Analysis was performed in Minitab using the Analysis of Variance (ANOVA) statistical 
test with a Tukey’s post-hoc test. 
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Figure 1 
 
 
 
 
Figure 1. Chemical structures and radical scavenging ability of antioxidants. (a) The 
chemical structures of Proxison, myricetin, and quercetin. (b,c) Galvinoxyl EPR spectra in the 
absence or presence of 2.5 µM (b) or 5 µM (c) antioxidants. (d) The percentage of the galvinoxyl 
radical remaining after incubation with 2.5 µM or 5 µM of Proxison, myricetin and quercetin.  
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Figure 2 
 
 
 
Figure 2. Antioxidant protection against acute oxidative stress. (a) Metabolic activity of SH-
SY5Y cells treated with 400 µM tBHP for 4 hours in the absence or presence of differing 
concentrations of 6 antioxidants (n=3). (b) Phase-contrast microscopy of tBHP-treated SH-SH5Y 
cells treated with DMSO (vehicle), myricetin, quercetin, or Proxison. Scale bar, 75 µm. (c) tBHP-
induced cytotoxicity was determined at 16 hours with the LDH assay in the absence or presence of 
4 antioxidants (n=3). (d) The percentage of dead cells was assessed at 16 hours by PI FACS 
analysis for Proxison-treated cells (n=2). ANOVA with a Tukey’s post-hoc test was performed to 
assess the significant difference between antioxidant-treated and vehicle-treated cells in (a), (c), 
and (d); ** p<0.01, *** p<0.001. 
  
	 12 
Figure 3 
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Figure 3. Cellular uptake and subcellular localisation of antioxidants. (a) Cellular uptake and 
localization was observed in SH-SY5Y cells. Cells were incubated with Proxison, quercetin, 
myricetin or DMSO (vehicle) before fixing, counterstaining with DAPI (blue), and confocal imaging, 
scale bar: 11 µm. (b) Subcellular localisation of Proxison was assessed by co-incubation with 
Mitotracker Deep Red prior to fixation and confocal imaging, scale bar: 11 µm. (c) Representative 
FACS plots of SH-SY5Y cells incubated with Proxison, quercetin, myricetin or DMSO (vehicle) for 
2 hours. Mean green fluorescence of live cells incubated with each antioxidant showed a 
significant uptake of Proxison and quercetin (n=2). (d) Proxison or MitoQ at 10 µM significantly 
rescued cytotoxicity due to tBHP treatment (p<0.01), but Proxison was significantly more effective 
than MitoQ when directly compared (p<0.05). ANOVA with a post-hoc Tukey test was performed; * 
p<0.05, ** p<0.01, *** p<0.001. 
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Figure 4 
 
 
 
 
Figure 4. Intracellular scavenging of tBHP-induced radicals by antioxidants. (a) Intracellular 
ROS production in SH-SY5Y cells treated with tBHP in the absence or presence of Proxison (10 
µM), quercetin (100 µM), or myricetin (100 µM) was observed with CellROX® Deep Red. Scale 
bar: 40 µm. (b) The average intensity of CellROX® Deep Red (far red) fluorescence of cells in the 
five conditions were quantified with Volocity software. Bars represent the mean from four 
independent experiments with duplicate cover slips for Proxison, and two independent experiments 
for quercetin and myricetin. Error bars represent the SEM. ANOVA with the post-hoc Tukey test 
was performed to assess significant difference to vehicle-treated cells; ** p<0.01, *** p<0.001. 
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Figure 5 
 
 
 
Figure 5. Proxison reduces tBHP-induced NRF2 oxidative stress response and prevents 8-
OHdG DNA oxidative damage. (a) tBHP-treated SH-SY5Y cells in the absence or presence of 
Proxison were fixed and immunostained for NRF2 (red), 8-OHdG (green), and counterstained for 
the nuclear marker DAPI (blue). Scale bar: 60 µm. (b,c) The intensity of NRF2 red fluorescence (b) 
and 8-OHdG green fluorescence (c) in the nuclei as quantified using ImageJ. Bars in (b) and (c) 
represent the mean of three coverslips from independent experiments (n=3) with 2-4 images per 
coverslip, error bars represent the SEM. (d) RNA was extracted from similarly treated cells to 
measure gene expression of NRF2, NQO1 and HMOX1 relative to TATA-binding protein (TBP). 
Bars represent the mean of duplicate or triplicate wells (n=2-3). Error bars represent the standard 
deviation. ANOVA with the Tukey’s post-hoc test was performed in (b), (c) and (d) to assess 
significant difference to vehicle-treated cells; * p<0.05, *** p<0.001. 
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Figure 6 
 
 
 
 
Figure 6. Antioxidant protection against 6-OHDA-induced dopaminergic cell death in 
zebrafish embryos. (a) Zebrafish embryos at 24 hours post-fertilisation (hpf) were treated with 6-
OHDA for 24 hours in the presence or absence of the antioxidants Proxison or quercetin (10 µM). 
Embryos were then fixed at 48 hpf, immunostained for TH (red) and confocal images were taken of 
the embryo head viewed from the top, scale bar: 50 µm. (b) The number of TH-positive cells in 
each embryo was counted for each treatment group (control, n=28; vehicle, n=30; Proxison, n=26, 
quercetin, n=24). Bars represent the mean number of TH-positive cells and error bars show the 
SEM. ANOVA with Tukey’s post-hoc test was performed to assess the significant difference to the 
6-OHDA treated embryos; * p<0.05, *** p<0.001. 
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Supplementary Figure 1 
 
 
 
Supplementary Figure 1. tBHP-induced cellular toxicity. SH-SY5Y cells were incubated with 
various concentrations of tBHP for 5 hours with the MTS assay being performed in the last hour to 
assess cell viability. Bars represent the mean from 3 independent experiments (n=3), each with 
triplicate wells, error bars represent the SEM. ANOVA with a Tukey’s post-hoc test was performed 
to assess the significant difference between tBHP-treated cells and vehicle-treated cells, * p<0.05.  
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Supplementary Movie 1 
Videomicroscopy of SH-SY5Y cells treated with 400 µM tBHP for 5h. Live cell imaging obtained 
with the Cell-IQ system. Cells exhibit morphological signs of lipid peroxidation and death.  
 
Supplementary Movie 2 
Videomicroscopy of SH-SY5Y cells treated with 400 µM tBHP in the presence of 1 µM Proxison for 
5h. Live cell imaging obtained with the Cell-IQ system. Cells exhibit small amounts of membrane 
blebbing, but otherwise remain healthy and alive after 5h. 
 
 
Supplementary Figure 2 
 
 
 
Supplementary Figure 2. tBHP treated cells in the absence or presence of Proxison. Images 
from Cell-IQ videomicroscopy of SH-SY5Y cells at 0h, 2.5h, and 5h. Proxison (1 µM ) fully protects 
cells against a high-dose of tBHP (400 µM). Scale bar, 75 µm. 
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Supplementary Figure 3 
 
 
 
 
Supplementary Figure 3. tBHP-induced cellular toxicity is rescued by Proxison and 
quercetin in Neuroscreen-1™ rat cells. Neuroscreen-1 cells were incubated with 400 uM of 
tBHP for 5 hours in the absence or presence of varying concentrations of Proxison, myricetin, or 
quercetin. The MTS assay was performed in the last hour to assess cell viability. Bars represent 
the mean from 3 independent experiments. ANOVA with a Tukey’s post-hoc test was performed to 
assess the significant difference between tBHP-treated cells and antioxidant-treated cells, *** 
p<0.001.   
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Supplementary Figure 4 
 
 
 
Supplementary Figure 4. Flavonoid antioxidants naturally fluoresce green. The fluorescence 
of Proxison, myricetin, and quercetin (1 mM) in DMSO was assessed using the FLUOstar 
microplate reader with excitation 485 nm and emission 520 nm (n=4). Error bars represent the 
standard error of the mean (SEM). 
 
